Professor Shi Yehui commented on the update of the medical insurance directory of 2021, and the new cancer indications for immunotherapy were approved

On July 1, the "Top Ten Progress in the Cancer Field of the Public Public Most Incurities in 2021" was launched in "I do practical practice activities for the masses · Healthy Chinese Oncology Prevention and Control (2022-2023) and" Tumor's Things "column launched The launching ceremony was officially released.

(The above comments are from the executive member of the Breast Cancer Professional Committee of the China Anti -Cancer Association of Shi Yehui and chief physician of the Department of Breakstum of Breast and Oncology at the Cancer Hospital of Tianjin Medical University)

Immunotherapy, especially PD-1/PD-L1 antibody drugs, has become the most noticeable new drug in the field of malignant tumor treatment in recent years. The earliest publication of PD-1/PD-L1 antibody drugs was Paborzab. At that time, the indications at the time were only treated with second-line melanoma, but as the research deepened, more and more drugs entered the clinic. And in the treatment of a variety of malignant tumors, it has achieved remarkable achievements, especially for some cancer species that have lacking treatment measures, such as malignant melanoma, kidney cancer, liver cell liver cancer, soft tissue sarcoma, etc. Become the most important treatment of these patients.

At the same time, my country's independently developed PD-1/PD-L1 antibody drugs have been developing rapidly, and 9 drugs have been listed, of which the four most important products (Karelizumab, for Rei Lilizabi, Cindei Mipide and Tripley Mipide) have obtained the second line of Hodgkin lymphatic pain, the second line of the liver cancer, the second line of esophageal cancer, the first line of nasopharyngeal cancer, the first line of nasopharyngeal cancer, and the lung cancer squamous non -small cells. Pulmonary cancer, first line of esophageal cancer, melanoma. Urinary trail cancer second-line, liver cancer first/second line, physical tumor MSI-H/dmmr second line and other indications have been successfully shortlisted in this year's medical insurance negotiations and included in medical insurance. This is great news for the vast number of malignant tumors in my country! These four drugs not only make up for the available shortcomings of imported drugs, but also reduce the economic burden on the majority of cancer patients in my country. After entering the medical insurance directory this year, the patient's own expense has been further reduced, which relieves the cancer patients in my country to the greatest extent. The stubborn illness of seeing a doctor reflects the basic policy of solving the medical needs of the people in the Chinese government.

- END -